The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
The company announced positive topline data from the Phase 3 ADorable-1 trial
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
Subscribe To Our Newsletter & Stay Updated
